Evaluating the risk of patient re-identification from adverse drug event reports

Abstract

BACKGROUND Our objective was to develop a model for measuring re-identification risk that more closely mimics the behaviour of an adversary by accounting for repeated attempts at matching and verification of matches, and apply it to evaluate the risk of re-identification for Canada's post-marketing adverse drug event database (ADE).Re-identification is only demonstrably plausible for deaths in ADE. A matching experiment between ADE records and virtual obituaries constructed from Statistics Canada vital statistics was simulated. A new re-identification risk is considered, it assumes that after gathering all the potential matches for a patient record (all records in the obituaries that are potential matches for an ADE record), an adversary tries to verify these potential matches. Two adversary scenarios were considered: (a) a mildly motivated adversary who will stop after one verification attempt, and (b) a highly motivated adversary who will attempt to verify all the potential matches and is only limited by practical or financial considerations. METHODS The mean percentage of records in ADE that had a high probability of being re-identified was computed. RESULTS Under scenario (a), the risk of re-identification from disclosing the province, age at death, gender, and exact date of the report is quite high, but the removal of province brings down the risk significantly. By only generalizing the date of reporting to month and year and including all other variables, the risk is always low. All ADE records have a high risk of re-identification under scenario (b), but the plausibility of that scenario is limited because of the financial and practical deterrent even for highly motivated adversaries. CONCLUSIONS It is possible to disclose Canada's adverse drug event database while ensuring that plausible re-identification risks are acceptably low. Our new re-identification risk model is suitable for such risk assessments.

DOI: 10.1186/1472-6947-13-114

Extracted Key Phrases

5 Figures and Tables

Cite this paper

@inproceedings{Emam2013EvaluatingTR, title={Evaluating the risk of patient re-identification from adverse drug event reports}, author={Khaled El Emam and Fida Kamal Dankar and Angelica Neisa and Elizabeth Jonker}, booktitle={BMC Med. Inf. & Decision Making}, year={2013} }